Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)

被引：5
|
作者：
Powles, T. B. [1 ]
Kopyltsov, E. [2 ]
Su, P-J. [3 ]
Parnis, F. X. [4 ]
Park, S. H. [5 ]
Yamamoto, Y. [6 ]
Fong, P. C. [7 ,8 ]
Tournigand, C. [9 ]
Duran, M. A. Climent [10 ]
Bamias, A. [11 ]
Caserta, C. [12 ]
Chang, J. [13 ]
Yan, E. [14 ]
di Pietro, A. [15 ]
Wang, J. [16 ]
Grivas, P. [17 ]
机构：
[1] Queen Mary Univ London, St Bartholomews Hosp, Expt Canc Med Ctr, Dept Med Oncol,Barts Canc Inst, London, England
[2] State Inst Healthcare Reg Clin Oncol Dispensary, Dept Med Oncol, Omsk, Russia
[3] Chang Gung Mem Hosp, Dept Oncol, Linkuo, Taiwan
[4] Univ Adelaide, Dept Med Oncol, Adelaide Canc Ctr, Adelaide, SA, Australia
[5] Sungkyunkwan Univ, Div Hematol Oncol, Dept Internal Med, Samsung Med Ctr, Seoul, South Korea
[6] Yamaguchi Univ, Dept Urol, Ube, Yamaguchi, Japan
[7] Univ Auckland, Dept Med Oncol, Auckland, New Zealand
[8] Auckland City Hosp, Auckland, New Zealand
[9] Paris Est Creteil Univ, Hop Henri Mondor, AP HP, Dept Med Oncol, Creteil, France
[10] Inst Valenciano Oncol, Dept Med Oncol, Valencia, Spain
[11] Natl & Kapodistrian Univ Athens, Sch Med, Dept Internal Med, Alexandra Gen Hosp, Athens, Greece
[12] Azienda Osped S Maria, Med Oncol Unit, Terni, Italy
[13] Pfizer, Global HEOR, New York, NY USA
[14] Pfizer, Biostat, La Jolla, CA USA
[15] Pfizer SRL, Immunooncol, Milan, Italy
[16] Pfizer, Biostat, Cambridge, MA USA
[17] Univ Washington, Div Med Oncol, Dept Med, Fred Hutchinson Canc Res Ctr, Seattle, MA USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.817
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
745P
引用
收藏
页码：S578 / S579
页数：2
相关论文
共 50 条
  • [1] Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100
    Grivas, P.
    Park, S. H.
    Voog, E.
    Caserta, C.
    Perez Valderrama, B.
    Gurney, H.
    Kalofonos, H.
    Radulovic, S.
    Demey, W.
    Ullen, A.
    Loriot, Y.
    Sridhar, S. S.
    Tsuchiya, N.
    Kopyltsov, E.
    Gupta, S.
    Huang, B.
    Costa, N.
    Blake-Haskins, J. A.
    di Pietro, A.
    Powles, T. B.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S555 - S556
  • [2] Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
    Yoshihiko Tomita
    Yoshiaki Yamamoto
    Norihiko Tsuchiya
    Hiroomi Kanayama
    Masatoshi Eto
    Hideaki Miyake
    Thomas Powles
    Mizuki Yoshida
    Yuichiro Koide
    Yoshiko Umeyama
    Alessandra di Pietro
    Hirotsugu Uemura
    [J]. International Journal of Clinical Oncology, 2022, 27 : 383 - 395
  • [3] Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
    Tomita, Yoshihiko
    Yamamoto, Yoshiaki
    Tsuchiya, Norihiko
    Kanayama, Hiroomi
    Eto, Masatoshi
    Miyake, Hideaki
    Powles, Thomas
    Yoshida, Mizuki
    Koide, Yuichiro
    Umeyama, Yoshiko
    di Pietro, Alessandra
    Uemura, Hirotsugu
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (02) : 383 - 395
  • [4] Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone in Asian patients with advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis.
    Eto, Masatoshi
    Lee, Jae-Lyun
    Park, Se Hoon
    Tsuchiya, Norihiko
    Su, Po-Jung
    Chan, T. W.
    Desai, Chirag Jyotiker
    Di Pietro, Alessandra
    Wang, Jing
    Laliberte, Robert J.
    Gao, Seasea
    Gurney, Howard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [5] Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.
    Tsuchiya, Norihiko
    Yamamoto, Yoshiaki
    Uemura, Hirotsugu
    Kanayama, Hiro-Omi
    Eto, Masatoshi
    Miyake, Hideaki
    Powles, Thomas
    Yoshida, Mizuki
    Koide, Yuichiro
    Umeyama, Yoshiko
    Di Pietro, Alessandra
    Tomita, Yoshikiko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [6] Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis
    Lee, Jae-Lyun
    Desai, Chirag
    Park, Se Hoon
    Tsuchiya, Norihiko
    Su, Po-Jung
    Chan, Timothy Tim Wai
    Gurney, Howard
    Gao, Seasea
    Wang, Jing
    Sandner, Robin
    di Pietro, Alessandra
    Eto, Masatoshi
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 256.e17 - 256.e25
  • [7] Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
    Powles, T. B.
    Loriot, Y.
    Bellmunt, J.
    Sternberg, C. N.
    Sridhar, S.
    Petrylak, D. P.
    Tambaro, R.
    Dourthe, L. M.
    Alvarez-Fernandez, C.
    Aarts, M.
    Mu, X. J.
    Ching, K. A.
    Pu, J.
    Roychoudhury, S.
    Davis, C. B.
    di Pietro, A.
    Grivas, P.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S552 - S553
  • [8] Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.
    Grivas, Petros
    Park, Se Hoon
    Voog, Eric
    Kopyltsov, Evgeny
    Gurney, Howard
    Muniz, David Queiroz Borges
    Rolland, Frederic
    Als, Anne Birgitte
    Valderrama, Begona P.
    Wang, Jing
    Costa, Nuno Matos
    Laliberte, Robert J.
    Di Pietro, Alessandra
    Powles, Thomas
    Bellmunt, Joaquim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma
    Grivas, Petros
    Kopyltsov, Evgeny
    Su, Po-Jung
    Parnis, Francis X.
    Park, Se Hoon
    Yamamoto, Yoshiaki
    Fong, Peter C.
    Tournigand, Christophe
    Duran, Miguel A. Climent
    Bamias, Aristotelis
    Caserta, Claudia
    Chang, Jane
    Cislo, Paul
    di Pietro, Alessandra
    Wang, Jing
    Powles, Thomas
    [J]. EUROPEAN UROLOGY, 2023, 83 (04) : 320 - 328
  • [10] Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.
    Loriot, Yohann
    Powles, Thomas
    Duran, Climent Miguel Angel
    Sridhar, Srikala S.
    Bellmunt, Joaquim
    Petrylak, Daniel Peter
    Wang Jing
    Costa, Nuno Matos
    Laliberte, Robert J.
    Di Pietro, Alessandra
    Grivas, Petros
    Sternberg, Cora N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345